Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) is inviting applications to form the Acquired Resistance to Therapy Network (ARTNet).
The ARTNet FOA is a reissuance that builds upon the Drug Resistance and Sensitivity Network (DRSN, RFA-CA-17-009) to focus
study on the mechanistic basis of acquired resistance to cancer therapies and disease recurrence.
Central to the ARTNets structural organization is team science approaches that iteratively bridge basic, pre-clinical, and translational research along the tumor-microenvironment continuum to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies.
This FOA will be published in parallel with a companion FOA titled Coordinating and Data Management Center (CDMC) for Acquired Resistance to Therapy Network (ARTNet; U24 Clinical Trial Not Allowed).